drugset
Drugs / LY4050784
last change 10 days ago re-read 9 days ago

LY4050784

targets SMARCA2 via inhibition

Developed for
metastatic neoplasm · non-small cell lung carcinoma
Investigated by
Eli Lilly and Company

Trials 1

today NCT06561685 · Ph 1
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06561685 Sep 2024 → Oct 2027 expected metastatic neoplasm, non-small cell lung carcinoma Eli Lilly and Company Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2026-10-01 Foghorn Therapeutics Inc. Results Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities foghorntx.com ↗
Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase.
2026-04-21 Foghorn Therapeutics Inc. Results Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting foghorntx.com ↗
today presented new preclinical data for Selective SMARCA2 inhibitor FHD-909 showing complete and durable tumor regression together with anti-tumor immune memory following combination treatment with an anti-PD-1 antibody in preclinical syngeneic mouse models.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LY4050784 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06561685 ↗
Action Inhibit “a Selective SMARCA2/BRM Inhibitor” NCT06561685 ↗
Route Oral “Oral” NCT06561685 ↗
Target SMARCA2 “a Selective SMARCA2/BRM Inhibitor” NCT06561685 ↗